What is the CJC-1295 & Ipamorelin Stack?
In preclinical endocrinology and cell biology research, the combination of CJC-1295 (a Growth Hormone Releasing Hormone analog) and Ipamorelin (a selective Growth Hormone Secretagogue Receptor agonist) is widely studied for its dual-action signaling mechanism. By targeting different pathways on the pituitary gland, these compounds work in synergy to promote natural, pulsatile growth hormone secretion.
Unlike older growth hormone secretagogues that triggered massive, non-selective hormone releases, this combination is highly selective. It stimulates growth hormone release without producing undesirable spikes in cortisol, prolactin, or aldosterone. This selectivity makes it a preferred model for injury recovery, muscle tissue synthesis, joint repair, and body composition research.
When buying research peptides online, selecting a vendor that provides third-party HPLC analysis is critical. Suppliers like Amino Club offer co-lyophilized CJC-1295 + Ipamorelin stacks at >99% purity. Applying checkout coupon code MINUS20 provides a flat 20% discount, reducing the price to $68.00 per 10mg vial.
Pulsatile Growth Hormone Release Mechanism (GHRH vs GHRP)
To understand the synergy between CJC-1295 and Ipamorelin, researchers must examine how the body regulates growth hormone. The pituitary gland releases growth hormone in response to two primary signals: Growth Hormone-Releasing Hormone (GHRH) and Ghrelin.
CJC-1295 acts as a GHRH analog. It binds to the GHRH receptor on somatotropes in the anterior pituitary, initiating the synthesis and release of growth hormone. However, if GHRH is administered alone, its effects are limited by somatostatin—the hormone that blocks growth hormone release.
Ipamorelin acts as a Growth Hormone Releasing Peptide (GHRP) or Ghrelin mimetic. It binds to the Ghrelin receptor (growth hormone secretagogue receptor, or GHSR). This binding has two effects: it stimulates the release of growth hormone, and it actively suppresses somatostatin.
When stacked, CJC-1295 increases the quantity of growth hormone ready for release, while Ipamorelin clears the somatic blockades. This leads to a synergistic growth hormone surge that is significantly larger than the sum of their individual effects.
The Difference Between CJC-1295 With DAC and Without DAC
CJC-1295 exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also known as Mod GRF 1-29). The inclusion of the Drug Affinity Complex completely alters the peptide's pharmacokinetics.
DAC binds to blood albumin, extending the half-life of CJC-1295 from approximately 30 minutes to over 7 days. While this allows for infrequent dosing, it causes continuous, non-pulsatile growth hormone elevation. This condition is known as growth hormone bleed and can lead to pituitary desensitization and insulin resistance.
CJC-1295 without DAC (Mod GRF 1-29) has a short half-life of 30 minutes. This allows the peptide to clear the system quickly, maintaining the body's natural, pulsatile growth hormone release rhythm. For laboratory research that aims to mimic natural endocrine patterns, CJC-1295 without DAC is the preferred compound.
Key Benefits Identified in Research Models
Preclinical studies indicate that the CJC-1295 and Ipamorelin stack yields significant metabolic and cellular repair benefits. These effects are mediated by increased levels of circulating IGF-1 (Insulin-like Growth Factor 1).
Key parameters observed in laboratory research include:
- Accelerated Tissue Recovery: Enhanced protein synthesis speeds up the repair of micro-tears in muscle fiber and connective tissues.
- Adipose Tissue Reduction: Growth-hormone-induced lipolysis increases the mobilization of free fatty acids, targeting visceral fat deposits.
- Bone Mineral Density Support: Somatotropic activation upregulates osteoblast activity, supporting skeletal integrity.
- Mitochondrial Vitality: The stack supports mitochondrial respiration, helping to counter age-related cellular decline.
Clinical Safety, Cortisol, and Prolactin Profiles
A major issue with early GHRPs, such as Hexarelin and GHRP-6, was their lack of receptor selectivity. They triggered significant spikes in cortisol (the primary stress hormone) and prolactin (which can cause unwanted side effects like gynecomastia in models).
Ipamorelin is the most selective GHRP developed. In clinical trials, it demonstrated no statistically significant effect on cortisol or prolactin levels, even at high doses. CJC-1295 also shares this high safety profile.
Because the stack does not trigger these hormonal spikes, researchers can isolate the effects of growth hormone and IGF-1 on cellular repair without confounding variables.
Reconstitution Math & Syringe Calibration Chart
To prepare the stack for evaluation, the lyophilized powder must be mixed with bacteriostatic water. The most common packaging is a co-lyophilized 10mg vial (containing 5mg of CJC-1295 and 5mg of Ipamorelin).
If you add 2.0ml of bacteriostatic water to a 10mg co-lyophilized vial, the concentration is 2.5mg (2500mcg) of CJC-1295 and 2.5mg (2500mcg) of Ipamorelin per 1.0ml of solution.
Using a standard U-100 insulin syringe (100 units = 1.0ml), here is the calibration chart for dosing:
- 5 Units on Syringe (0.05ml): Provides 125mcg of CJC-1295 and 125mcg of Ipamorelin.
- 10 Units on Syringe (0.10ml): Provides 250mcg of CJC-1295 and 250mcg of Ipamorelin.
- 15 Units on Syringe (0.15ml): Provides 375mcg of CJC-1295 and 375mcg of Ipamorelin.
- 20 Units on Syringe (0.20ml): Provides 500mcg of CJC-1295 and 500mcg of Ipamorelin.
Always run the water down the inside glass wall of the vial to protect the delicate peptide bonds from breaking.
Dosage Protocols and Reconstitution Guidelines
In scientific literature, the CJC-1295 (without DAC) and Ipamorelin combination is typically evaluated at equal ratios, such as 1:1. The most common stack contains 5mg of CJC-1295 and 5mg of Ipamorelin in a single vial, or co-lyophilized for reconstitution convenience.
For a standard 10mg co-lyophilized vial, researchers typically add 2.0 ml of sterile bacteriostatic water. Dilution must be handled slowly by running the diluent down the inner glass wall, avoiding mechanical agitation, and storing the reconstituted liquid immediately at 2-8°C. Once mixed, the solution should be used within 30 days to ensure chemical stability.
Pituitary Somatotrope Refractory Periods & Cycle Length
Somatotropes—the cells in the anterior pituitary responsible for growth hormone production—experience a temporary refractory period after a secretagogue-induced release. Adminsitering GHRH and GHRP compounds too frequently will result in diminishing returns as somatotrope cells exhaust their immediate hormone stores.
Preclinical models indicate that a minimum window of 3 to 4 hours is required between exposures to allow somatotropes to synthesize and store new vesicles of growth hormone. If a study requires multiple administrations per day, they are typically scheduled in the morning and immediately before nocturnal sleep cycles.
To prevent systemic desensitization, research protocols rarely run continuous secretagogue cycles indefinitely. A standard study layout spans 8 to 12 weeks, followed by a washout period of 4 weeks. This washout phase allows pituitary receptors to clear and return to baseline sensitivity levels.
Dietary Strategies to Enhance Stack Efficacy
Growth hormone release is highly sensitive to metabolic signals, specifically circulating levels of glucose and insulin. Elevated blood glucose and the subsequent insulin spike strongly inhibit growth hormone secretion by activating somatostatin pathways.
For research models to achieve maximum somatotropic output, administrations must occur during a state of fasting. The general benchmark is to withhold nutrients for at least 2 to 3 hours before administration, and wait 30 to 45 minutes afterward before introducing carbohydrates or fats.
Maintaining a low-insulin environment ensures that the pituitary receptors can respond to the synergistic signals of CJC-1295 and Ipamorelin without metabolic interference.
Cost-Efficiency Calculations for Multi-Vial Cycles
When planning a long-term research study, calculating the volume of compounds needed is essential to budget allocation. An 8-week (56 days) validation study using a daily dosage of 250mcg of CJC-1295 and 250mcg of Ipamorelin requires a total of 14,000mcg (14mg) of each compound.
Using separate 5mg vials of each peptide requires sourcing three vials of CJC-1295 and three vials of Ipamorelin, which totals six vials. This often results in higher retail prices and double the reconstitution steps.
By choosing the co-lyophilized Wolverine or standard CJC + Ipa stack (10mg total: 5mg CJC-1295 + 5mg Ipamorelin) from Amino Club, the study requires exactly three vials. Sourced with the checkout promo code MINUS20, the total expense drops from $255.00 to $204.00, reducing laboratory overhead while simplifying storage and compounding metrics.